<DOC>
	<DOCNO>NCT00301860</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy donor peripheral blood stem cell transplant help stop growth cancer cell patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient , may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving chemotherapy , fludarabine melphalan , antithymocyte globulin transplant cyclosporine methotrexate transplant may stop happen . PURPOSE : This clinical trial study well donor stem cell transplant , use low-dose chemotherapy antithymocyte globulin , follow donor white blood cell infusion work treat young patient hematologic cancer .</brief_summary>
	<brief_title>Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions Treating Young Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility allogeneic hematopoietic stem cell transplantation use reduced-intensity conditioning regimen , term whole blood engraftment rate 100 day post transplant , pediatric patient hematopoietic malignancy high risk complication conventional transplantation . - Determine feasibility donor lymphocyte infusion ( DLIs ) , term number patient receive least one DLI 12 month post transplant , patient treat regimen . - Determine toxicity condition regimen , term 100-day post transplant nonrelapse-related death rate , patient . - Determine toxicity DLI , term acute chronic graft-vs-host disease rate 12-month post transplant nonrelapse-related death rate , patient . OUTLINE : This pilot study . - Reduced-intensity conditioning regimen : Patients receive fludarabine IV day -6 -2 ; antithymocyte globulin IV day -5 -2 ; melphalan IV day -3 -2 . - Transplantation : Patients undergo allogeneic peripheral blood stem cell transplantation day 0 . Patients also receive filgrastim ( G-CSF ) IV begin day 5 continue blood count recover . - Graft-vs-host disease ( GVHD ) prophylaxis : Patients receive cyclosporine IV orally begin day -1 continue least day 28 methotrexate IV day 1 , 3 , 6 . - Donor lymphocyte infusion ( DLI ) : Patients mixed chimerism , acute GVHD require therapy , relapse/progression post transplant day 90 may receive DLI . At least 30 day discontinuation immunosuppression , patient may receive 2 DLIs least 8-12 week apart absence GVHD . At completion study treatment , patient follow periodically 2 year . PROJECTED ACCRUAL : A total 10 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis one follow hematopoietic malignancy : Acute lymphoblastic leukemia myeloid leukemia &lt; 30 % blast bone marrow Juvenile myelomonocytic leukemia Chronic myelogenous leukemia chronic accelerate phase Relapsed nonHodgkin 's Hodgkin 's lymphoma least partial remission Considered high risk ( &gt; 30 % ) toxic death standard hematopoietic stem cell transplantation ( HSCT ) , indicate least one following : Creatinine &gt; 1.5 time normal OR creatinine clearance &lt; 70 mL/min OR tubular damage correct cessation chemotherapy DLCO &lt; 60 % predict OR history prior intubation due lung disease ( intubation surgery exclude ) Shortening fraction &lt; 30 % History disseminate fungal infection chemotherapy OR currently receive antifungal agent OR history ≥ 2 septic episode ( confirmed culture ) require ICU support Patients improve fungal infection eligible Improving infection define confirmed negative culture 2 separate occasion , least 1 week apart , and/or stable improve image study ( e.g. , CT scan ) infect site Two image study take least 2 week apart must show stable improved disease History stroke abnormal MRI/MRA OR leukoencephalopathy OR seizures fully control anticonvulsant ( &gt; 2 episode seizure precede year 1 episode status epilepticus patient receive anticonvulsant therapy ) History prior significant bleeding ( e.g. , pulmonary , CNS , gastrointestinal ) OR history clot disorder manifest prior significant thromboses ( e.g. , superior vena cava , inferior vena cava , femoral vein ) Failed conventional therapy eligible myeloablative protocol May fail prior conventional HSCT No active CNS leukemia Unrelated relate donor available , meet follow criterion : Matched least 7/8 loci highresolution type One mismatch A , B , C locus allow Fully match DRB1 locus PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 02 OR Karnofsky PS 60100 % No active/progressing viral , bacterial , protozoal , fungal infection Transaminases ≤ 5 time normal ( except presence autoimmune liver disease ) Shortening fraction ≥ 25 % DLCO ≥ 40 % OR pulse oximetry ≥ 85 % room air Glomerular filtration rate ≥ 40 mL/min PRIOR CONCURRENT THERAPY : See Disease Characteristics Prior prolong intensive chemotherapy ( &gt; 3 year therapy ≥ 3 different chemotherapeutic protocol ) allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
</DOC>